SRPT (Sarepta Therapeutics, Inc.) Stock Financials & Earnings | Market Cap Arena

SRPT (Sarepta Therapeutics, Inc.) Stock Financials & Earnings | Market Cap Arena

SRPTSarepta Therapeutics, Inc.

Mkt Cap$2B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$2.2B

Net Income (TTM)-$713M

EPS (TTM)-$8.44

Free Cash Flow (TTM)-$317M

Gross Margin59.9%

Op. Margin-29.9%

Net Margin-32.5%

FCF Margin-14.4%

P/S Ratio (TTM)0.9x

P/E Ratio (TTM)—

YoY Rev Growth+15.6%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$254M	$218M	-$138M
Q2 23	$261M	$227M	-$134M
Q3 23	$332M	$295M	-$21M
Q4 23	$397M	$353M	$25M
Q1 24	$413M	$363M	$35M
Q2 24	$363M	$318M	-$701K
Q3 24	$467M	$375M	$22M
Q4 24	$658M	$526M	$162M
Q1 25	$745M	$607M	-$300M
Q2 25	$611M	$459M	$116M
Q3 25	$399M	$249M	-$103M
Q4 25	$443M	$2M	-$370M

Valuation

Quarter	P/S	P/E
Q1 23	1.9x	—
Q2 23	1.9x	—
Q3 23	1.7x	—
Q4 23	1.5x	—
Q1 24	1.3x	112.0x
Q2 24	1.3x	40.0x
Q3 24	1.2x	15.5x
Q4 24	1.0x	8.0x
Q1 25	0.8x	—
Q2 25	0.8x	—
Q3 25	0.8x	—
Q4 25	0.9x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$209M	-$219M
Q2 23	-$122M	-$140M
Q3 23	-$115M	-$155M
Q4 23	-$55M	-$74M
Q1 24	-$242M	-$285M
Q2 24	$15M	-$14M
Q3 24	-$71M	-$108M
Q4 24	$92M	$54M
Q1 25	-$583M	-$629M
Q2 25	$261M	$229M
Q3 25	-$15M	-$43M
Q4 25	$131M	$125M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$10M
Q2 23	$18M
Q3 23	$41M
Q4 23	$19M
Q1 24	$42M
Q2 24	$29M
Q3 24	$37M
Q4 24	$38M
Q1 25	$46M
Q2 25	$32M
Q3 25	$28M
Q4 25	$6M

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	+20.2%	+31.5%
Q2 23	+11.9%	-11.2%
Q3 23	+44.1%	-2.5%
Q4 23	+53.5%	+1.9%
Q1 24	+63.1%	-3.3%
Q2 24	+38.9%	-7.9%
Q3 24	+40.8%	+26.2%
Q4 24	+65.9%	+33.5%
Q1 25	+80.2%	+176.1%
Q2 25	+68.4%	+36.3%
Q3 25	-14.5%	+13.0%
Q4 25	-32.7%	+63.6%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$41M	16.3%
Q2 23	$47M	18.1%
Q3 23	$48M	14.5%
Q4 23	$46M	11.5%
Q1 24	$41M	9.8%
Q2 24	$50M	13.9%
Q3 24	$43M	9.3%
Q4 24	$50M	7.5%
Q1 25	$41M	5.6%
Q2 25	$37M	6.1%
Q3 25	$15M	3.7%
Q4 25	$30M	6.8%

OpEx Breakdown

Quarter	R&D	G&A
Q1 23	$246M	$111M
Q2 23	$242M	$119M
Q3 23	$194M	$121M
Q4 23	$196M	$132M
Q1 24	$200M	$127M
Q2 24	$180M	$139M
Q3 24	$224M	$128M
Q4 24	$200M	$164M
Q1 25	$773M	$134M
Q2 25	$204M	$138M
Q3 25	$219M	$92M
Q4 25	$325M	$116M

Revenue by Geography

Quarter	Rest of World	United States
Q1 25	$375M	$375M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$872M	$1.0B	$1.9B
Q2 23	$852M	$1.0B	$1.9B
Q3 23	$542M	$1.2B	$1.7B
Q4 23	$428M	$1.2B	$1.7B
Q1 24	$427M	$963M	$1.4B
Q2 24	$384M	$1.1B	$1.5B
Q3 24	$198M	$1.0B	$1.2B
Q4 24	$1.1B	$252M	$1.4B
Q1 25	$241M	$282M	$523M
Q2 25	$511M	$290M	$800M
Q3 25	$613M	$238M	$851M
Q4 25	$801M	$138M	$940M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	88M	+0.4%
Q2 23	89M	+0.6%
Q3 23	89M	+0.2%
Q4 23	106M	+18.8%
Q1 24	99M	-6.1%
Q2 24	99M	+0.0%
Q3 24	100M	+1.3%
Q4 24	108M	+8.0%
Q1 25	97M	-10.2%
Q2 25	107M	+9.5%
Q3 25	100M	-6.0%
Q4 25	105M	+4.5%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 14	$48K	204
FY 15	$5K	270
FY 16	$28K	197
FY 17	$606K	255
FY 18	$603K	499
FY 19	$513K	743
FY 20	$624K	866
FY 21	$836K	840
FY 22	$803K	1K
FY 23	$946K	1K
FY 24	$1M	1K
FY 25	$11K	200K